Troculeucel may boost cognition, new Alzheimer’s data shows
NKGen Biotech is making strides in Alzheimer’s treatment with its experimental therapy, Troculeucel, which harnesses patient-specific natural killer (NK) cells to potentially enhance cognitive function. At the upcoming AD/PD 2026 conference, the company will present early-phase trial data indicating that this cell-based approach may lead to improvements in memory and thinking for individuals with moderate Alzheimer’s disease.
This innovative therapy shifts the paradigm from symptom management to leveraging the immune system to combat disease processes. By enhancing NK cells in the lab and reintroducing them to patients, Troculeucel aims to bolster the brain’s defenses against cognitive decline. Preliminary findings suggest a correlation between reduced brain inflammation, indicated by lower GFAP levels, and cognitive improvements, marking a significant step forward in Alzheimer’s research.
As the field of longevity science evolves, Troculeucel exemplifies how cell therapies could redefine approaches to cognitive health. For a deeper dive into these promising findings, I recommend exploring the full article.